Responses
Regular and Young Investigator Award Abstracts
Biomarkers, Immune Monitoring, and Novel Technologies
30 Blood-based glycoprotein signatures in advanced non-small-cell lung carcinoma (NSCLC) receiving first-line immune checkpoint blockade
Compose a Response to This Article
Other responses
No responses have been published for this article.